002603 以岭药业
交易中 08-13 10:27:15
资讯
新帖
简况
以岭药业(002603.SZ):化药创新药“LB220-D08缓释片”药物临床试验申请获得受理
智通财经 · 08-12 17:00
以岭药业(002603.SZ):化药创新药“LB220-D08缓释片”药物临床试验申请获得受理
以岭药业:未来将更加重视现金分红
证券之星 · 08-05
以岭药业:未来将更加重视现金分红
以岭药业:7月21日高管赵韶华增持股份合计100股
证券之星 · 07-22
以岭药业:7月21日高管赵韶华增持股份合计100股
7月20日以岭药业涨6.67%,长信金利趋势混合A基金重仓该股
证券之星 · 07-20
7月20日以岭药业涨6.67%,长信金利趋势混合A基金重仓该股
以岭药业茂丰绿科驴肉被纳入全国特质农品名录 国字号品质认证再添硕果
证券之星 · 07-13
以岭药业茂丰绿科驴肉被纳入全国特质农品名录 国字号品质认证再添硕果
“国字号”认证!以岭药业茂丰鸡蛋入选全国特质农品名录
证券之星 · 07-13
“国字号”认证!以岭药业茂丰鸡蛋入选全国特质农品名录
7月13日以岭药业涨6.19%,长信金利趋势混合A基金重仓该股
证券之星 · 07-13
7月13日以岭药业涨6.19%,长信金利趋势混合A基金重仓该股
以岭药业获评“2025星岛环球中国・杰出领袖出海企业”
证券之星 · 07-10
以岭药业获评“2025星岛环球中国・杰出领袖出海企业”
以岭药业(002603)披露公司及全资子公司7个专利产品进入《国家基本药物目录》(2026年版),7月9日股价下跌1.24%
证券之星 · 07-09
以岭药业(002603)披露公司及全资子公司7个专利产品进入《国家基本药物目录》(2026年版),7月9日股价下跌1.24%
以岭药业最新公告:全资孙公司获厄贝沙坦原料药上市批准
证券之星 · 07-06
以岭药业最新公告:全资孙公司获厄贝沙坦原料药上市批准
以岭药业:联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放
证券之星 · 07-03
以岭药业:联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放
以岭药业:现金分红是公司回报股东的重要方式之一
证券之星 · 07-03
以岭药业:现金分红是公司回报股东的重要方式之一
以岭药业:小儿连花情感颗粒新药注册上市申请已获正式受理
证券之星 · 07-03
以岭药业:小儿连花情感颗粒新药注册上市申请已获正式受理
以岭药业:已有连翘、金银花、酸枣等多个种植基地通过了GAP延伸检查
证券之星 · 07-03
以岭药业:已有连翘、金银花、酸枣等多个种植基地通过了GAP延伸检查
以岭药业:八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品
证券之星 · 07-03
以岭药业:八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品
6月29日以岭药业涨6.00%,长信金利趋势混合A基金重仓该股
证券之星 · 06-29
6月29日以岭药业涨6.00%,长信金利趋势混合A基金重仓该股
以岭药业连续4年参评,2025报告获评“四星半级”|评级档案(编号1927)
证券之星 · 05-25
以岭药业连续4年参评,2025报告获评“四星半级”|评级档案(编号1927)
以岭药业最新公告:全资孙公司磷酸奥司他韦原料药上市申请获批
证券之星 · 05-14
以岭药业最新公告:全资孙公司磷酸奥司他韦原料药上市申请获批
以岭药业:构建专利中药、化生药、健康产业协同发展格局
证券之星 · 05-14
以岭药业:构建专利中药、化生药、健康产业协同发展格局
每周股票复盘:以岭药业(002603)股东户数较前期减少1.8%
证券之星 · 05-03
每周股票复盘:以岭药业(002603)股东户数较前期减少1.8%
加载更多
公司概况
公司名称:
石家庄以岭药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-07-28
主营业务:
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊/颗粒、连花清咳片、芪防鼻通片、津力达颗粒、通络明目胶囊、益肾养心安神片、解郁除烦胶囊、枣椹安神口服液、养正消积胶囊、参灵蓝胶囊、八子补肾胶囊、夏荔芪胶囊、乳结泰胶囊、妇血安片。公司荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。
发行价格:
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":17.11,"timestamp":1786588035000,"preClose":16.78,"halted":0,"volume":17964380,"delay":0,"changeRate":0.0197,"floatShares":1377000000,"shares":1671000000,"eps":0.8197,"marketStatus":"交易中","change":0.33,"latestTime":"08-13 10:27:15","open":16.77,"high":17.27,"low":16.58,"amount":305000000,"amplitude":0.0411,"askPrice":17.1,"askSize":10,"bidPrice":17.09,"bidSize":28,"shortable":0,"etf":0,"ttmEps":0.8197,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1786591800000},"marketStatusCode":2,"adr":0,"adjPreClose":16.78,"symbolType":"stock","openAndCloseTimeList":[[1786584600000,1786591800000],[1786597200000,1786604400000]],"highLimit":18.46,"lowLimit":15.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.46,"roa":"--","peRate":20.87349,"roe":"3.65%","epsLYR":0.77,"committee":-0.819579,"marketValue":28586000000,"turnoverRate":0.0131,"status":0,"floatMarketCap":23552000000},"requestUrl":"/m/hq/s/002603","defaultTab":"news","newsList":[{"id":"2658978437","title":"以岭药业(002603.SZ):化药创新药“LB220-D08缓释片”药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978437","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658978437?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:00","pubTimestamp":1786525244,"startTime":"0","endTime":"0","summary":"智通财经APP讯,以岭药业(002603.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,该药物名称:“LB220-D08缓释片”。LB220-D08为公司自主研发的全新小分子化学药物,是公司具有独立知识产权的1类化学新药。本品为靶向FactorB因子的补体抑制剂。通过靶向抑制B因子,本品可选择性抑制旁路途径,阻止C3转化酶的活化,从而抑制C3a、C5a等毒素的生成以及C5转化酶和膜攻击复合物(MAC,C5b-9)的形成,并保持凝集素和经典途径信号通路的正常功能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","MEDX","PSYK","BK1574","IBBJ","BMED","IBBQ","BK0042","06978","MDTX","BK0097","LNGR","BK0239","BK0046","BK1161","002603","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657512105","title":"以岭药业:未来将更加重视现金分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2657512105","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657512105?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:00","pubTimestamp":1785920450,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业08月05日在投资者关系平台上答复投资者关心的问题。公司未来,也将根据实际经营业绩情况,在符合公司利润分配政策、保障公司正常运营和长远发展的前提下,会更加重视现金分红,更好地回报广大股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500030872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0042","BK0239","002603","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653768770","title":"以岭药业:7月21日高管赵韶华增持股份合计100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653768770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653768770?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:01","pubTimestamp":1784725305,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月22日市场公开信息、上市公司公告及交易所披露数据整理,以岭药业最新董监高及相关人员股份变动情况:2026年7月21日公司高管赵韶华共增持公司股份100.0股,占公司总股本为0.0001%。以岭药业近半年内的董监高及核心技术人员增减持详情如下:以岭药业的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入1051.63万,融资余额增加;融券净流出25.02万,融券余额减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200045517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","002603","BK0188","BK0097","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652296123","title":"7月20日以岭药业涨6.67%,长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652296123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652296123?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:41","pubTimestamp":1784536886,"startTime":"0","endTime":"0","summary":"证券之星消息,7月20日以岭药业涨6.67%,收盘报17.6元,换手率4.69%,成交量64.59万手,成交额11.09亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。长信金利趋势混合A目前规模为35.61亿元,最新净值0.3943,较上一交易日下跌0.15%,近一年上涨27.87%。长信金利趋势混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0188","BK0042","BK0097","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651719796","title":"以岭药业茂丰绿科驴肉被纳入全国特质农品名录 国字号品质认证再添硕果","url":"https://stock-news.laohu8.com/highlight/detail?id=2651719796","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651719796?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:13","pubTimestamp":1783933997,"startTime":"0","endTime":"0","summary":"近日,经农业农村部农产品质量安全中心多轮严格评审,以岭药业全资子公司故城县茂丰农业科技开发有限公司旗下的茂丰绿科驴肉被纳入全国特质农品名录,获评国家级特质农品称号。特质农品的入选门槛堪称严苛,需要经过全维度层层闯关考核。本次获选,标志着茂丰公司在特色农业领域的品质实力获得国家级权威认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026071300024987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","BK0097","BK0046","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651936197","title":"“国字号”认证!以岭药业茂丰鸡蛋入选全国特质农品名录","url":"https://stock-news.laohu8.com/highlight/detail?id=2651936197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651936197?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:12","pubTimestamp":1783933945,"startTime":"0","endTime":"0","summary":"近日,经农业农村部农产品质量安全中心多轮严格评审,以岭药业全资子公司故城县茂丰农业科技开发有限公司旗下的茂丰鸡蛋成功登录全国特质农品名录,获颁国家级特质农品证书。本次茂丰鸡蛋被纳入全国特质农品名录,不仅是官方和行业对茂丰鸡蛋独特风味、稳定品质的充分肯定,更成为茂丰公司特色种养殖产业品质升级的标志性成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026071300024943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0046","BK0188","BK0042","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651606192","title":"7月13日以岭药业涨6.19%,长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651606192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651606192?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:46","pubTimestamp":1783932371,"startTime":"0","endTime":"0","summary":"证券之星消息,7月13日以岭药业涨6.19%,收盘报16.47元,换手率4.17%,成交量57.45万手,成交额9.47亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。长信金利趋势混合A目前规模为35.61亿元,最新净值0.3943,较上一交易日下跌0.15%,近一年上涨27.87%。长信金利趋势混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300023687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","002603","BK0239","BK0046","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650885891","title":"以岭药业获评“2025星岛环球中国・杰出领袖出海企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2650885891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650885891?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:44","pubTimestamp":1783669463,"startTime":"0","endTime":"0","summary":"7月9日,星岛新闻集团“2025杰出领袖选举”颁奖晚宴在深圳、香港两地同步举办。以岭药业凭借在中医药现代化与国际化领域的突出贡献,荣获“2025星岛环球中国杰出领袖出海企业”奖项。作为获奖企业代表,以岭药业在国际化进程中走出了一条独特路径。据悉,“2025星岛环球中国·杰出领袖出海企业”奖项由星岛新闻集团首次发起设立,旨在表彰在中国企业全球化进程中取得卓越成就的行业标杆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026071000024428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0097","BK0188","BK0239","BK0042","BK0046","BK1130","01105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650204049","title":"以岭药业(002603)披露公司及全资子公司7个专利产品进入《国家基本药物目录》(2026年版),7月9日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650204049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650204049?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:19","pubTimestamp":1783606755,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘,以岭药业报收于15.19元,较前一交易日下跌1.24%,最新总市值为253.78亿元。近日,以岭药业披露《关于公司及全资子公司专利产品进入〈国家基本药物目录〉的公告》。公告显示,国家卫生健康委员会于2026年7月9日发布《国家基本药物目录》,自2026年9月1日起施行。上述产品均为公司独家专利中药,2025年合计收入606,920.11万元,占公司主营业务收入的77.50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","BK0097","BK0046","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640960","title":"以岭药业最新公告:全资孙公司获厄贝沙坦原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649640960?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:32","pubTimestamp":1783330334,"startTime":"0","endTime":"0","summary":"以岭药业(002603.SZ)公告称,公司全资孙公司万洋衡水制药有限公司收到国家药监局下发的《化学原料药上市申请批准通知书》,其提交的“厄贝沙坦”原料药上市申请获批。该药品用于原发性高血压及合并高血压的2型糖尿病肾病治疗,将丰富公司产品线,但短期内不会对当期业绩产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600024204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0042","002603","BK0046","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648261634","title":"以岭药业:联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放","url":"https://stock-news.laohu8.com/highlight/detail?id=2648261634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648261634?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:06","pubTimestamp":1783040766,"startTime":"0","endTime":"0","summary":"投资者提问:请问董秘,有看到网络消息,公司在2026年春节期间在高铁站有大量广告推广,是否属实,如果有是在哪些地方有增加广告,我在南京,上海,杭州等地都没有看到以岭药业回复:投资者您好,公司积极加强企业品牌和产品品牌建设,联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放,全面提升企业品牌形象与产品知名度,强化用户品牌记忆,从而助力产品终端销售转化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0097","002603","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648342606","title":"以岭药业:现金分红是公司回报股东的重要方式之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2648342606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648342606?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:01","pubTimestamp":1783040469,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业07月02日在投资者关系平台上答复投资者关心的问题。现金分红是公司回报股东的重要方式之一,通常情况下,持续稳定的分红也是企业稳健经营的标志之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","BK0097","BK0046","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648341746","title":"以岭药业:小儿连花情感颗粒新药注册上市申请已获正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2648341746","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648341746?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:58","pubTimestamp":1783040289,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业07月02日在投资者关系平台上答复投资者关心的问题。以岭药业回复:投资者您好,去年8月,公司中药创新药小儿连花情感颗粒新药注册上市申请已获正式受理,后续如有新的进展,公司将及时公告。17个产品中12个纳入国家医保目录,5个进入国家基药目录,在全球50余个国家上市销售,获专利870项,荣获国家科技进步奖等六项国家大奖。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0042","BK0239","002603","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648189634","title":"以岭药业:已有连翘、金银花、酸枣等多个种植基地通过了GAP延伸检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2648189634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648189634?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:54","pubTimestamp":1783040050,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业07月02日在投资者关系平台上答复投资者关心的问题。公司现有通过GAP认真基地多少亩?截至目前,以岭药业已有连翘、金银花、酸枣等多个种植基地通过了 GAP 延伸检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0046","BK0239","BK0097","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648341856","title":"以岭药业:八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2648341856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648341856?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:54","pubTimestamp":1783040049,"startTime":"0","endTime":"0","summary":"八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品,是通过填补肾精、燮理阴阳、温扶元气、充养形神实现抗衰老的代表性品种。研究结果显示,八子补肾胶囊可改善自然衰老小鼠的记忆力和肌肉耐力,逆转自然衰老小鼠增龄性的甲基化变化,显著降低其DNA甲基化年龄并延长其健康寿命。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0097","BK0188","BK0046","002603","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647391322","title":"6月29日以岭药业涨6.00%,长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647391322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647391322?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:43","pubTimestamp":1782722586,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日以岭药业涨6.00%创60日新低,收盘报15.54元,换手率1.98%,成交量27.19万手,成交额4.12亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。长信金利趋势混合A目前规模为35.61亿元,最新净值0.3943,较上一交易日下跌0.15%,近一年上涨27.87%。长信金利趋势混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","002603","BK0239","BK0042","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638945581","title":"以岭药业连续4年参评,2025报告获评“四星半级”|评级档案(编号1927)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638945581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638945581?lang=zh_cn&edition=full","pubTime":"2026-05-25 10:27","pubTimestamp":1779676078,"startTime":"0","endTime":"0","summary":"报告评级经“中国企业社会责任报告评级专家委员会”评定,《石家庄以岭药业股份有限公司2025年环境、社会及治理报告》为“四星半级”,是一份领先的企业可持续发展报告。亮点绩效《报告》的实质性、可比性均达到五星级,过程性、平衡性、可读性、创新性达到四星半级,完整性达到四星级。评级勋章以岭药业连续4年参与报告评级,获黄铜级勋章。以岭药业环境、社会及公司治理报告连续4年获评“四星半级”","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026052500008413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635754790","title":"以岭药业最新公告:全资孙公司磷酸奥司他韦原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2635754790","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635754790?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:33","pubTimestamp":1778751210,"startTime":"0","endTime":"0","summary":"以岭药业(002603.SZ)公告称,公司全资孙公司万洋衡水制药有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》,其提交的“磷酸奥司他韦”化学原料药上市申请已获批准。该药品用于预防和治疗流行性感冒,2025年奥司他韦制剂销售额为40.72亿元,同比增长15.03%。此次获批将丰富公司产品线,拓展业务领域,但不会对当期经营业绩产生重大影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400030716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0188","BK0239","BK0097","002603","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635501767","title":"以岭药业:构建专利中药、化生药、健康产业协同发展格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2635501767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635501767?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:54","pubTimestamp":1778720052,"startTime":"0","endTime":"0","summary":"石家庄以岭药业股份有限公司创建于1992年,是国内领先的中药创新企业,以络病理论为科学基石,自主研发17个专利中药新药,覆盖心脑血管、呼吸、抗衰老、代谢、神经、肿瘤等多个健康领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0097","BK0188","BK0046","002603","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632608571","title":"每周股票复盘:以岭药业(002603)股东户数较前期减少1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632608571","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632608571?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:12","pubTimestamp":1777767140,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,以岭药业报收于17.04元,较上周的16.67元上涨2.22%。本周,以岭药业4月28日盘中最高价报17.25元。以岭药业当前最新总市值284.69亿元,在中药板块市值排名8/66,在两市A股市值排名766/5200。本周关注点股本股东变化:股东户数较前期减少1.8%股本股东变化:户均持股市值为19.01万元股本股东变化股东户数变动截至2026年3月31日,公司股东户数为14.8万户,较12月31日减少2712.0户,减幅为1.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0042","002603","BK0097","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786588036598,"stockEarnings":[{"period":"1week","weight":0.0207},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0287},{"period":"6month","weight":-0.0044},{"period":"1year","weight":0.0948},{"period":"ytd","weight":0.0149}],"compareEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0084},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0332},{"period":"1year","weight":0.0766},{"period":"ytd","weight":-0.0056}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"148000人(较上一季度减少1.80%)","perCapita":"9300股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊/颗粒、连花清咳片、芪防鼻通片、津力达颗粒、通络明目胶囊、益肾养心安神片、解郁除烦胶囊、枣椹安神口服液、养正消积胶囊、参灵蓝胶囊、八子补肾胶囊、夏荔芪胶囊、乳结泰胶囊、妇血安片。公司荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}